Recent Updates
Recently added Catalysts
CGC Positive Sentiment

Canopy Growth Broadens Australian Medical Cannabis Portfolio With New Formats and Formulations

Key Takeaway: Canopy Growth Corporation has announced an expansion of its medical cannabis portfolio in Australia. This includes the introduction of two new product formats and new formulations within its existing oil and softgel ranges. The expansion is part of Canopy's ongoing commitment to improving lives through cannabis.

Market Sentiment Analysis

POSITIVE FACTORS

  • Canopy Growth is expanding its medical cannabis portfolio in Australia.
  • Introduction of new product formats and formulations enhances offerings.
  • The move reflects Canopy Growth's commitment to bettering lives through cannabis.

Full Press Release Details

SMITHS FALLS, Ontario--(BUSINESS WIRE)--Canopy Growth Corporation (“Canopy Growth”, “our”, “we” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a leading global company committed to bettering lives through cannabis, today announced a broadening of its medical cannabis portfolio in Australia across its Spectrum Therapeutics, Spectrum Therapeutics Reserve, 7ACRES, Tweed and Twd. brands. The expansion introduces two new product formats, and new formulations within its existing oil and softgel ranges.

Frequently Asked Questions

What new products did Canopy Growth introduce?

Canopy Growth introduced two new product formats and new formulations in its oil and softgel ranges.

Which brands are included in the expansion?

The expansion includes Spectrum Therapeutics, Spectrum Therapeutics Reserve, 7ACRES, Tweed, and Twd. brands.

What is the focus of Canopy Growth's expansion?

The focus is on broadening its medical cannabis portfolio in Australia.

Last updated: Sep 8, 2026